BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:rezatapopt readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of rezatapopt\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04585750-2704@assetmemo.bio
DTSTAMP:20261121T005348Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:rezatapopt: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:rezatapopt\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Th
 e Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a
  TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezatapopt#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0458575
 0
URL:https://assetmemo.bio/drug/rezatapopt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372625-2704@assetmemo.bio
DTSTAMP:20261121T005348Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:rezatapopt: Phase 1 readout est. (NCT07372625)
DESCRIPTION:rezatapopt\, phase 1.\nStudy: A Study to Investigate the Effect
 s of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin\, R
 osuvastatin\, Repaglinide\, and Midazolam in Patients With Advanced Solid 
 Tumors Harboring a TP53 Y220C Mutation.\nEstimated primary completion: Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezatapopt#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07372
 625
URL:https://assetmemo.bio/drug/rezatapopt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616636-2704@assetmemo.bio
DTSTAMP:20261121T005348Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:rezatapopt: Phase 1 readout est. (NCT06616636)
DESCRIPTION:rezatapopt\, phase 1.\nStudy: A Phase Ib Study of Rezatapopt in
  Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Ma
 lignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)\nEstimated
  primary completion: 27 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rezatapopt#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06616636
URL:https://assetmemo.bio/drug/rezatapopt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
